RESUMEN
Acute myeloid leukemia (AML), a heterogeneous hematopoietic cancer prevalent in adults, has been a leading cause of leukemia-associated deaths for decades. Despite advancements in understanding its pathology and pharmacological targets, therapeutic strategies have seen minimal change. The standard treatment, combining cytarabine and anthracycline, has persisted, accompanied by challenges such as pharmacokinetic issues and non-specific drug delivery, leading to severe side effects. Nanotechnology offers a promising solution through combination drug delivery. FDA-approved CPX351 (VYXEOS™) a liposomal formulation delivering doxorubicin and cytarabine, exemplifies enhanced therapeutic efficacy. Ongoing research explores various nanocarriers for delivering multiple bioactives, addressing drug targeting, pharmacokinetics and chemoresistance. This review highlights nanotechnology-based combination therapies for the effective management of AML, presenting a potential breakthrough in leukemia.
[Box: see text].
RESUMEN
BACKGROUND: As countries and industries continue to cope with the unparalleled challenges presented by the novel coronavirus (COVID-19), a specific area of concern has been the uncertainty surrounding the impact of the COVID-19 pandemic on the global and Indian supply chains of the pharmaceutical industry. The COVID-19 crisis has demonstrated the importance of establishing a risk management system that focuses on assessing future risks resulting from the loss of a supply chain among countries. OBJECTIVE: This review focuses on the role of the Indian pharmaceutical industry towards the pandemic. This review investigates the economic effect of COVID-19 across segments and what it implies for the Indian economy. METHODS: The COVID 19 flare-up has additionally commenced the Indian pharmaceutical organizations an opportunity to transform into a supported trade place point for gathering drugs and intermediates. RESULTS: An enormous pharmaceutical industry in India has consistently been a foundation of reasonable human services, and this pattern would now be able to be required to heighten further. CONCLUSION: The activities from COVID-19 are with a need to change the overall impression of Indian pharmaceutical associations and even more altogether, reduce the dependence of the private pharma associations on alone suppliers like China.